We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App





150 Million Rapid COVID-19 Tests from Abbott Begin Rolling out Across US

By LabMedica International staff writers
Posted on 30 Sep 2020
The US government has begun distribution of 150 million COVID-19 rapid point-of-care tests from Abbott (Lake Forest, IL, USA), doubling the number of tests that have already been performed across the nation.

In an update on the national coronavirus testing strategy, President Trump stated that the US had so far conducted 111 million COVID-19 tests, far more than any other country, more than the entire European Union and more than all of Latin America combined. More...
President Trump also announced a plan to distribute 150 million Abbott rapid point-of-care tests in the coming weeks. Abbott had recently entered into a deal worth USD 750 million with the US government to supply 150 million BinaxNOW COVID-19 Ag Card rapid tests for the detection of COVID-19 infection.

BinaxNOW is highly portable (about the size of a credit card), affordable at USD 5 and provides results in 15 minutes. The test uses proven Abbott lateral flow technology, making it a reliable and familiar format for frequent mass testing through their healthcare provider. It is intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset. With no equipment required, the device will be an important tool to manage risk by quickly identifying infectious people who are currently infected and who should isolate themselves to help prevent the spread of the disease.

President Trump revealed that out of the 150 million COVID-19 rapid POC tests from Abbott to be distributed across the US in the coming weeks, 50 million tests would be allocated to protect the most vulnerable communities, including 18 million tests for nursing homes; 15 million tests for assisted living facilities; 10 million tests for home, health, and hospice care agencies; and nearly one million tests for historically black colleges and universities, and also tribal nation colleges. Additionally, the US government plans to give 100 million COVID-19 rapid POC tests from Abbott to states and territories to support efforts to reopen their economies and schools immediately and fast as they can.

“These new Abbott rapid point-of-care tests are easy to use and return results within just minutes. You’ll have a result at a maximum 15 minutes. Machine — no machine is required to process them,” said President Trump. “So, in the old days, when we just started this, you remember we’d go out and we’d have to find these massive laboratories with tremendously expensive equipment. Now we’re down to something that you’ll see that is really from a different planet.”





Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.